Lamark Biotech’s thermostable biologics platform shows exactly how Indian founders are reimagining drug delivery for the world’s most underserved populations!
What is the news?
- Lamark Biotech, founded by Dr. Vaibhav Bhatia in 2018, has raised ₹6.5 crore in pre-Series A funding led by IAN Group, including IAN Alpha Fund and domain expert angel investors from IAN’s network.
- The Ahmedabad-based startup has developed the proprietary ProteoStrong platform that stabilizes fragile protein-based drugs like insulin, monoclonal antibodies, and enzymes without altering their molecular structure, addressing the critical cold-chain dependency in biologics.
Why is it interesting?
- This is healthcare accessibility at a massive scale. Lamark’s thermostable biologics can make critical treatments available in low-resource environments where cold storage infrastructure is limited. Their lead program, InsulinStrong, is targeting India’s ₹4,000 crore insulin market with expansion plans across Southeast Asia andthe UAE.
- The global expansion strategy is compelling, leveraging R&D capabilities from Venture Center’s innovation park in Pune, they’re planning international patents, clinical trials, and partnerships with pharma companies, CDMOs, and global health agencies within 24 months. Their platform extends beyond insulin to diabetic eye disease and cancer immunotherapy applications.
- This India-to-global approach of creating temperature-resilient biologics represents a massive opportunity to democratize access to life-saving treatments for millions across underserved regions globally.
Read more: Innovation-led biopharma startup Lamark Biotech raises Rs 6.5 crore in funding